Fractyl Health, Inc.

Fractyl reported second-quarter 2026 research and development expense of $13.8 million versus $21.2 million a year ago, SG&A of $5.3 million versus $4.9 million, net loss of $25.5 million versus $27.9 million, and adjusted EBITDA of negative $16.3 million versus negative $24.0 million. Cash and cash equivalents were $47.1 million as of June 30, 2026, and cash used in operations was approximately $16 million in Q2. Management said the company remains on track to report top-line 6-month REMAIN-1 pivotal data in early Q4 2026, 12-month data in Q1 2027, and a potential de novo submission in late Q4 2026.

Harith Rajagopalan framed Revita as a potential third option for patients who discontinue GLP-1s: durable, drug-free weight maintenance after a one-time endoscopic procedure. He repeatedly emphasized that the clinical signal is now supported by randomized sham-controlled 1-year data and that the pivotal study is designed to replicate those results at larger scale. His tone was confident and commercially focused, stressing that the market is already forming, physicians already see these patients, and payers are increasingly concerned about indefinite GLP-1 use, discontinuation, and affordability.

Lara Weber highlighted lower second-quarter spending, with R&D down $7.3 million year over year to $13.8 million, mainly from reduced Revita and Rejuva spending, while SG&A rose modestly to $5.3 million due to stock compensation. The company reported a net loss of $25.5 million and adjusted EBITDA of negative $16.3 million, both improved from the prior-year quarter, and said Q2 cash used in operations of about $16 million better reflects the post-randomization run rate than Q1. She said the $47.1 million cash balance should fund operations into early 2027, beyond the expected pivotal readout and through a potential de novo submission.

Analysts focused on profitability, reimbursement, pricing, physician ramp, and regulatory path. Management declined to give specific procedure-volume assumptions or pricing, but said physician training appears to take fewer than five procedures and that the company expects to use a preceptorship model at a targeted set of top endoscopy centers. On coverage, management said it expects payers to scrutinize the studied population and pointed to transitional pass-through reimbursement as a potential launch-day tailwind; on FDA path, it said the key issue for de novo is the pivotal safety dataset and that FDA feedback to date on the SAP was not material.